Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens well-tolerated across Phase 1 High receptor occupancy (RO) in Phase 1 SAD study confirmed by MAD results

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to present

Expanded research and development collaboration with Janssen for third integrin program Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 Received acceptance to present full MORF-057 Phase 1 data set at the ECCO’21 Virtual Congress in July Completed $245 million

Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to its

First data from oral αvβ8 program demonstrate potent anti-tumor response through TGFβ pathway Combination with checkpoint inhibitor showed efficacy in checkpoint-resistant models of breast cancer and induced a lasting anti-tumor effect WALTHAM, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Morphic

WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of

WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a proposed underwritten public offering in which it intends to

MORF-057 well tolerated in all dose cohorts MORF-057 achieved greater than 95% mean receptor occupancy of α4β7 integrin at three highest dose levels; demonstrates ability to saturate α4β7 receptor Data provide early clinical proof of concept for MORF-057 as an oral, selective α4β7 inhibitor Phase 1

Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 AbbVie exercised license option to αvβ6 integrin inhibitor program for fibrotic diseases Expanded research and development collaboration with Janssen through third integrin program Conference call today at 8:00 a.m.

Call to discuss financial and operational results for fiscal year 2020 and MORF-057 interim data from SAD portion of ongoing MORF-057 Phase 1 clinical trial WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation